	US 11,690,837 B2
	Methods of improving cell-based therapy
Nipavan Chiamvimonvat, Davis, CA (US); and Bruce D. Hammock, Davis, CA (US)
Assigned to THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US)
Filed by THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US)
Filed on Jun. 19, 2019, as Appl. No. 16/446,353.
Application 16/446,353 is a division of application No. 15/915,637, filed on Mar. 8, 2018, granted, now 10,369,141.
Application 15/915,637 is a continuation of application No. 14/737,263, filed on Jun. 11, 2015, abandoned.
Claims priority of provisional application 62/012,422, filed on Jun. 16, 2014.
Prior Publication US 2019/0365733 A1, Dec. 5, 2019
Int. Cl. A61K 31/4468 (2006.01); A61K 35/545 (2015.01); A61K 31/195 (2006.01); A61K 31/336 (2006.01); A61K 35/34 (2015.01); A61L 31/00 (2006.01); A61L 31/16 (2006.01); A61K 9/70 (2006.01); A61K 31/17 (2006.01); A61K 31/197 (2006.01); A61K 31/22 (2006.01); A61K 31/415 (2006.01); A61K 31/4465 (2006.01); A61K 35/28 (2015.01)

CPC A61K 31/4468 (2013.01) [A61K 9/7023 (2013.01); A61K 31/17 (2013.01); A61K 31/195 (2013.01); A61K 31/197 (2013.01); A61K 31/22 (2013.01); A61K 31/336 (2013.01); A61K 31/415 (2013.01); A61K 31/4465 (2013.01); A61K 35/28 (2013.01); A61K 35/34 (2013.01); A61K 35/545 (2013.01); A61L 31/005 (2013.01); A61L 31/16 (2013.01); A61L 2300/432 (2013.01); A61L 2300/64 (2013.01); A61L 2430/20 (2013.01)]

18 Claims

1. A stent comprising a population of induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) and one or more agents that increase the production and/or level of epoxygenated fatty acids, wherein the one or more agents that increase the production and/or level of epoxygenated fatty acids is:

(1) a synthetic cis-Epoxyeicosatrienoic acid (“EET”);

(2) an inhibitor of soluble epoxide hydrolase (“sEH”) having an IC50 of less than about 10 nM; or

(3) an inhibitor of sEH comprising a primary pharmacophore selected from the group consisting of a urea, a carbamate, and an amide.